Review



pre coated microplate strips  (Sino Biological)


Bioz Verified Symbol Sino Biological is a verified supplier
Bioz Manufacturer Symbol Sino Biological manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Sino Biological pre coated microplate strips
    Pre Coated Microplate Strips, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pre+coated+microplate+strips/pmc13120400-60-6-9?v=Sino+Biological
    Average 94 stars, based on 2 article reviews
    pre coated microplate strips - by Bioz Stars, 2026-08
    94/100 stars

    Images



    Similar Products

    pre coated microplate strips  (Sino Biological)
    94
    Sino Biological pre coated microplate strips
    Pre Coated Microplate Strips, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pre+coated+microplate+strips/pmc13120400-60-6-9?v=Sino+Biological
    Average 94 stars, based on 1 article reviews
    pre coated microplate strips - by Bioz Stars, 2026-08
    94/100 stars
    		  Buy from Supplier
    pre-coated gal3 specific 96 well strip microplates elisa kit  (Absolute Biotech Inc)
    90
    Absolute Biotech Inc pre-coated gal3 specific 96 well strip microplates elisa kit
    Comparison of circulating <t>gal3</t> levels in porcine model (SCD vs. survivors). Panel ( A ) shows comparison of circulating galectin-3 levels in survivors (N = 9) vs. SCD group (N = 5) approximately 3 months after the coronary intervention. Panel ( B ) shows the time-course of circulating galectin-3 increase with higher levels detected ~10 days before ventricular tachycardia/ventricular fibrillation (VT/VF) cardiac arrest, compared to the mean galectin-3 levels measured in the pigs that had no cardiac arrest. N = 3–11, *, p = 0.0036 10 days before cardiac arrest vs. 20 days before cardiac arrest in SCD pigs, †, p = 0.0002 10 days before cardiac arrest in SCD vs. survivors pigs. ( C , D ) shows representative immunofluorescence images of galectin-3-stained pig left ventricular sections with non-SCD and SCD. The bar diagram ( E ) in the lower panel shows a significantly increased level of galectin-3 in these animals. N = 5 per group. CTF, corrected total fluorescent intensity. Scale bar: 50 µm, magnification ×400.
    Pre Coated Gal3 Specific 96 Well Strip Microplates Elisa Kit, supplied by Absolute Biotech Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pre+coated+microplate+strips/pmc10177039-146-7-9?v=Absolute+Biotech+Inc
    Average 90 stars, based on 1 article reviews
    pre-coated gal3 specific 96 well strip microplates elisa kit - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    pre-coated anti-crp microplate strips  (Boster Bio)
    90
    Boster Bio pre-coated anti-crp microplate strips
    Comparison of circulating <t>gal3</t> levels in porcine model (SCD vs. survivors). Panel ( A ) shows comparison of circulating galectin-3 levels in survivors (N = 9) vs. SCD group (N = 5) approximately 3 months after the coronary intervention. Panel ( B ) shows the time-course of circulating galectin-3 increase with higher levels detected ~10 days before ventricular tachycardia/ventricular fibrillation (VT/VF) cardiac arrest, compared to the mean galectin-3 levels measured in the pigs that had no cardiac arrest. N = 3–11, *, p = 0.0036 10 days before cardiac arrest vs. 20 days before cardiac arrest in SCD pigs, †, p = 0.0002 10 days before cardiac arrest in SCD vs. survivors pigs. ( C , D ) shows representative immunofluorescence images of galectin-3-stained pig left ventricular sections with non-SCD and SCD. The bar diagram ( E ) in the lower panel shows a significantly increased level of galectin-3 in these animals. N = 5 per group. CTF, corrected total fluorescent intensity. Scale bar: 50 µm, magnification ×400.
    Pre Coated Anti Crp Microplate Strips, supplied by Boster Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pre+coated+microplate+strips/pmc09101272-97-12-14?v=Boster+Bio
    Average 90 stars, based on 1 article reviews
    pre-coated anti-crp microplate strips - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    a pre-coated galectin-3 specific 96-well strip microplate enzyme-linked immunosorbent assays (elisa) kit  (R&D Systems)
    90
    R&D Systems a pre-coated galectin-3 specific 96-well strip microplate enzyme-linked immunosorbent assays (elisa) kit
    Myocardial gene expression of <t>galectin-3</t> after acute MI in mice. Panel A: Representative Trichrome-labeled section from infarct region. Panel B: Similarly stained section from remote region. The data columns represent fold-change of mRNA expression at different time-points of genomic profiling after acute MI induction. Panel C: Maximal galectin-3 expression was noted at 7-21 days with a chronic elevation present till 90 days post-MI. N = 3, each group; total, 8 time-points. * P < .05, 1-4 days vs 7-21 days; ** P < .05, 7-21 days vs 45-90 days. Panel D: The remote region showed minimal and statistically non-significant galectin-3 mRNA expression over time. MI indicates myocardial infarction.
    A Pre Coated Galectin 3 Specific 96 Well Strip Microplate Enzyme Linked Immunosorbent Assays (Elisa) Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pre+coated+microplate+strips/pmc05946633-141-2-16?v=R%26D+Systems
    Average 90 stars, based on 1 article reviews
    a pre-coated galectin-3 specific 96-well strip microplate enzyme-linked immunosorbent assays (elisa) kit - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Comparison of circulating gal3 levels in porcine model (SCD vs. survivors). Panel ( A ) shows comparison of circulating galectin-3 levels in survivors (N = 9) vs. SCD group (N = 5) approximately 3 months after the coronary intervention. Panel ( B ) shows the time-course of circulating galectin-3 increase with higher levels detected ~10 days before ventricular tachycardia/ventricular fibrillation (VT/VF) cardiac arrest, compared to the mean galectin-3 levels measured in the pigs that had no cardiac arrest. N = 3–11, *, p = 0.0036 10 days before cardiac arrest vs. 20 days before cardiac arrest in SCD pigs, †, p = 0.0002 10 days before cardiac arrest in SCD vs. survivors pigs. ( C , D ) shows representative immunofluorescence images of galectin-3-stained pig left ventricular sections with non-SCD and SCD. The bar diagram ( E ) in the lower panel shows a significantly increased level of galectin-3 in these animals. N = 5 per group. CTF, corrected total fluorescent intensity. Scale bar: 50 µm, magnification ×400.

    Journal: Cells

    Article Title: Galectin-3 Is Associated with Cardiac Fibrosis and an Increased Risk of Sudden Death

    doi: 10.3390/cells12091218

    Figure Lengend Snippet: Comparison of circulating gal3 levels in porcine model (SCD vs. survivors). Panel ( A ) shows comparison of circulating galectin-3 levels in survivors (N = 9) vs. SCD group (N = 5) approximately 3 months after the coronary intervention. Panel ( B ) shows the time-course of circulating galectin-3 increase with higher levels detected ~10 days before ventricular tachycardia/ventricular fibrillation (VT/VF) cardiac arrest, compared to the mean galectin-3 levels measured in the pigs that had no cardiac arrest. N = 3–11, *, p = 0.0036 10 days before cardiac arrest vs. 20 days before cardiac arrest in SCD pigs, †, p = 0.0002 10 days before cardiac arrest in SCD vs. survivors pigs. ( C , D ) shows representative immunofluorescence images of galectin-3-stained pig left ventricular sections with non-SCD and SCD. The bar diagram ( E ) in the lower panel shows a significantly increased level of galectin-3 in these animals. N = 5 per group. CTF, corrected total fluorescent intensity. Scale bar: 50 µm, magnification ×400.

    Article Snippet: For circulating gal3 measurement, we used a pre-coated gal3 (LSBio, Seattle, WA kit #LSF32161) specific 96 well strip microplates ELISA kit.

    Techniques: Comparison, Immunofluorescence, Staining

    Myocardial gene expression of galectin-3 after acute MI in mice. Panel A: Representative Trichrome-labeled section from infarct region. Panel B: Similarly stained section from remote region. The data columns represent fold-change of mRNA expression at different time-points of genomic profiling after acute MI induction. Panel C: Maximal galectin-3 expression was noted at 7-21 days with a chronic elevation present till 90 days post-MI. N = 3, each group; total, 8 time-points. * P < .05, 1-4 days vs 7-21 days; ** P < .05, 7-21 days vs 45-90 days. Panel D: The remote region showed minimal and statistically non-significant galectin-3 mRNA expression over time. MI indicates myocardial infarction.

    Journal: Biomarker Insights

    Article Title: The Therapeutic Potential of Blocking Galectin-3 Expression in Acute Myocardial Infarction and Mitigating Inflammation of Infarct Region: A Clinical Outcome-Based Translational Study

    doi: 10.1177/1177271918771969

    Figure Lengend Snippet: Myocardial gene expression of galectin-3 after acute MI in mice. Panel A: Representative Trichrome-labeled section from infarct region. Panel B: Similarly stained section from remote region. The data columns represent fold-change of mRNA expression at different time-points of genomic profiling after acute MI induction. Panel C: Maximal galectin-3 expression was noted at 7-21 days with a chronic elevation present till 90 days post-MI. N = 3, each group; total, 8 time-points. * P < .05, 1-4 days vs 7-21 days; ** P < .05, 7-21 days vs 45-90 days. Panel D: The remote region showed minimal and statistically non-significant galectin-3 mRNA expression over time. MI indicates myocardial infarction.

    Article Snippet: To measure serum galectin-3, a pre-coated galectin-3 specific 96-well strip microplate Enzyme-linked Immunosorbent Assays (ELISA) kit (R&D Systems; Minneapolis, MN, USA) was used, and optical densities were analyzed with standard galectin-3 concentrations (at ng/mL) based on the manufacturer’s recommendations.

    Techniques: Expressing, Labeling, Staining

    Post-MI myocardial galectin-3 expression and macrophage infiltration 1 week after LAD ligation. Wild-type mice showed scattered areas of galectin-3 positivity (Panel A1), which was absent in the myocardial sections obtained from galectin-3 KO mice (Panel A2). Panel A3 represents isotype control for galectin-3 antibody. Panel A4 represents quantitative analysis of Panels A1 and A2 (7 myocardial fields, each group). The macrophage-specific F4/80 staining in WT mice showed abundant positively stained cells in the infarct (red arrow) and peri-infarct (blue arrow) regions, especially in the areas of excess cardiomyocyte loss (Panel B1). The galectin-3 KO mice showed reduced F4/80 positive cellular infiltration compared with WT mice (Panel B2). Panel B3 represents isotype control for mouse F4/80 antibody. Panel B4 represents quantitative analysis of Panels B1 and B2 (12 myocardial fields, each group). KO indicates knock-out; LAD, left anterior descending; MI, myocardial infarction; WT, wild-type. * P < .05.

    Journal: Biomarker Insights

    Article Title: The Therapeutic Potential of Blocking Galectin-3 Expression in Acute Myocardial Infarction and Mitigating Inflammation of Infarct Region: A Clinical Outcome-Based Translational Study

    doi: 10.1177/1177271918771969

    Figure Lengend Snippet: Post-MI myocardial galectin-3 expression and macrophage infiltration 1 week after LAD ligation. Wild-type mice showed scattered areas of galectin-3 positivity (Panel A1), which was absent in the myocardial sections obtained from galectin-3 KO mice (Panel A2). Panel A3 represents isotype control for galectin-3 antibody. Panel A4 represents quantitative analysis of Panels A1 and A2 (7 myocardial fields, each group). The macrophage-specific F4/80 staining in WT mice showed abundant positively stained cells in the infarct (red arrow) and peri-infarct (blue arrow) regions, especially in the areas of excess cardiomyocyte loss (Panel B1). The galectin-3 KO mice showed reduced F4/80 positive cellular infiltration compared with WT mice (Panel B2). Panel B3 represents isotype control for mouse F4/80 antibody. Panel B4 represents quantitative analysis of Panels B1 and B2 (12 myocardial fields, each group). KO indicates knock-out; LAD, left anterior descending; MI, myocardial infarction; WT, wild-type. * P < .05.

    Article Snippet: To measure serum galectin-3, a pre-coated galectin-3 specific 96-well strip microplate Enzyme-linked Immunosorbent Assays (ELISA) kit (R&D Systems; Minneapolis, MN, USA) was used, and optical densities were analyzed with standard galectin-3 concentrations (at ng/mL) based on the manufacturer’s recommendations.

    Techniques: Expressing, Ligation, Staining, Knock-Out

    Comparison of serum galectin-3 level in healthy controls vs STEMI patients with either MACE-positive or MACE-negative outcome (Panel A) and in STEMI patients with reduced ejection fraction on ventriculogram (Panel B). Data are expressed as mean ± SEM. * P < .05 compared with control (Panel A); # P < .05 compared with MACE (Panel A); † P < .05 (Panel B). HF indicates heart failure; MACE, major adverse cardiovascular events defined as composite outcome of mortality, recurrent MI, stroke, and congestive HF hospitalization. MI, myocardial infarction; SEM, standard error of mean; STEMI, ST-elevation myocardial infarction.

    Journal: Biomarker Insights

    Article Title: The Therapeutic Potential of Blocking Galectin-3 Expression in Acute Myocardial Infarction and Mitigating Inflammation of Infarct Region: A Clinical Outcome-Based Translational Study

    doi: 10.1177/1177271918771969

    Figure Lengend Snippet: Comparison of serum galectin-3 level in healthy controls vs STEMI patients with either MACE-positive or MACE-negative outcome (Panel A) and in STEMI patients with reduced ejection fraction on ventriculogram (Panel B). Data are expressed as mean ± SEM. * P < .05 compared with control (Panel A); # P < .05 compared with MACE (Panel A); † P < .05 (Panel B). HF indicates heart failure; MACE, major adverse cardiovascular events defined as composite outcome of mortality, recurrent MI, stroke, and congestive HF hospitalization. MI, myocardial infarction; SEM, standard error of mean; STEMI, ST-elevation myocardial infarction.

    Article Snippet: To measure serum galectin-3, a pre-coated galectin-3 specific 96-well strip microplate Enzyme-linked Immunosorbent Assays (ELISA) kit (R&D Systems; Minneapolis, MN, USA) was used, and optical densities were analyzed with standard galectin-3 concentrations (at ng/mL) based on the manufacturer’s recommendations.

    Techniques: Comparison

    Comparison of early outcomes including length of hospitalization and early echocardiographic ( <72 hours) and angiographic (at time of PCI) parameters of myocardial dysfunction in STEMI patients in relation to galectin-3 level.

    Journal: Biomarker Insights

    Article Title: The Therapeutic Potential of Blocking Galectin-3 Expression in Acute Myocardial Infarction and Mitigating Inflammation of Infarct Region: A Clinical Outcome-Based Translational Study

    doi: 10.1177/1177271918771969

    Figure Lengend Snippet: Comparison of early outcomes including length of hospitalization and early echocardiographic ( <72 hours) and angiographic (at time of PCI) parameters of myocardial dysfunction in STEMI patients in relation to galectin-3 level.

    Article Snippet: To measure serum galectin-3, a pre-coated galectin-3 specific 96-well strip microplate Enzyme-linked Immunosorbent Assays (ELISA) kit (R&D Systems; Minneapolis, MN, USA) was used, and optical densities were analyzed with standard galectin-3 concentrations (at ng/mL) based on the manufacturer’s recommendations.

    Techniques: Comparison

    Demographic characteristics of STEMI patients and comparison between patients with and without MACE.

    Journal: Biomarker Insights

    Article Title: The Therapeutic Potential of Blocking Galectin-3 Expression in Acute Myocardial Infarction and Mitigating Inflammation of Infarct Region: A Clinical Outcome-Based Translational Study

    doi: 10.1177/1177271918771969

    Figure Lengend Snippet: Demographic characteristics of STEMI patients and comparison between patients with and without MACE.

    Article Snippet: To measure serum galectin-3, a pre-coated galectin-3 specific 96-well strip microplate Enzyme-linked Immunosorbent Assays (ELISA) kit (R&D Systems; Minneapolis, MN, USA) was used, and optical densities were analyzed with standard galectin-3 concentrations (at ng/mL) based on the manufacturer’s recommendations.

    Techniques: Comparison, Medications, Functional Assay

    Receiver-operating characteristic curve showing prediction of positive MACE outcome with galectin-3 compared with peak troponin and BNP. Area under the curve for galectin-3 is 0.914 (CI: 0.789-1.0; P < .05), BNP is 0.847 (CI: 0.709-0.985; P < .05), and peak troponin is 0.554 (CI: 0.258-0.851; P = .674). BNP indicates brain natriuretic peptide; CI, confidence interval; MACE, major adverse cardiovascular event.

    Journal: Biomarker Insights

    Article Title: The Therapeutic Potential of Blocking Galectin-3 Expression in Acute Myocardial Infarction and Mitigating Inflammation of Infarct Region: A Clinical Outcome-Based Translational Study

    doi: 10.1177/1177271918771969

    Figure Lengend Snippet: Receiver-operating characteristic curve showing prediction of positive MACE outcome with galectin-3 compared with peak troponin and BNP. Area under the curve for galectin-3 is 0.914 (CI: 0.789-1.0; P < .05), BNP is 0.847 (CI: 0.709-0.985; P < .05), and peak troponin is 0.554 (CI: 0.258-0.851; P = .674). BNP indicates brain natriuretic peptide; CI, confidence interval; MACE, major adverse cardiovascular event.

    Article Snippet: To measure serum galectin-3, a pre-coated galectin-3 specific 96-well strip microplate Enzyme-linked Immunosorbent Assays (ELISA) kit (R&D Systems; Minneapolis, MN, USA) was used, and optical densities were analyzed with standard galectin-3 concentrations (at ng/mL) based on the manufacturer’s recommendations.

    Techniques: